RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives
Abstract
:1. Introduction
2. Data Sources and Searches
3. RANK–RANKL–OPG Axis in Bone
3.1. Receptor Activator of NF-κB (RANK) and Receptor Activator of NF-κB Ligand (RANKL)
3.2. Osteoprotegerin (OPG)
4. RROa Studies in Murine Models
5. RROa in MASLD
5.1. Insulin Resistance
5.2. Macrophage Infiltration
5.3. Hepatic Fibrosis
5.4. Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL)
6. Targeting RROa with Medications: Denosumab
7. Anti-Osteoporotic Drugs for MASLD Treatment
8. RROa in Hepatocellular Carcinoma (HCC)
9. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Rinella, M.E.; Lazarus, J.V.; Ratziu, V.; Francque, S.M.; Sanyal, A.J.; Kanwal, F.; Romero, D.; Abdelmalek, M.F.; Anstee, Q.M.; Arab, J.P.; et al. A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature. J. Hepatol. 2023, 79, 1542–1556. [Google Scholar] [CrossRef] [PubMed]
- Powell, E.E.; Wong, V.W.-S.; Rinella, M. Non-Alcoholic Fatty Liver Disease. Lancet 2021, 397, 2212–2224. [Google Scholar] [CrossRef]
- Obesity and Overweight. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 7 June 2024).
- Marchesini, G.; Brizi, M.; Morselli-Labate, A.M.; Bianchi, G.; Bugianesi, E.; McCullough, A.J.; Forlani, G.; Melchionda, N. Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance. Am. J. Med. 1999, 107, 450–455. [Google Scholar] [CrossRef]
- Compston, J.E.; McClung, M.R.; Leslie, W.D. Osteoporosis. Lancet 2019, 393, 364–376. [Google Scholar] [CrossRef] [PubMed]
- Musio, A.; Perazza, F.; Leoni, L.; Stefanini, B.; Dajti, E.; Menozzi, R.; Petroni, M.L.; Colecchia, A.; Ravaioli, F. Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease. IJMS 2023, 24, 7517. [Google Scholar] [CrossRef] [PubMed]
- Chondrogianni, M.E.; Kyrou, I.; Androutsakos, T.; Flessa, C.-M.; Menenakos, E.; Chatha, K.K.; Aranan, Y.; Papavassiliou, A.G.; Kassi, E.; Randeva, H.S. Anti-Osteoporotic Treatments in the Era of Non-Alcoholic Fatty Liver Disease: Friend or Foe. Front. Endocrinol. 2024, 15, 1344376. [Google Scholar] [CrossRef]
- Yasuda, H. Discovery of the RANKL/RANK/OPG System. J. Bone Miner. Metab. 2021, 39, 2–11. [Google Scholar] [CrossRef]
- Bilezikian, J.P.; Martin, T.J.; Clemens, T.L.; Rosen, C. Principles of Bone Biology, 4th ed.; Academic Press: London, UK, 2020; ISBN 978-0-12-814841-9. [Google Scholar]
- Roodman, G.D. Advances in Bone Biology: The Osteoclast’. Endocr. Rev. 1996, 17, 308–332. [Google Scholar] [PubMed]
- Takahashi, N.; Akatsu, T.; Udagawa, N.; Sasaki, T.; Yamaguchi, A.; Moseley, J.M.; Martin, T.J.; Suda, T. OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION. Endocrinology 1988, 123, 2600–2602. [Google Scholar] [CrossRef]
- Xiong, J.; Cawley, K.; Piemontese, M.; Fujiwara, Y.; Zhao, H.; Goellner, J.J.; O’Brien, C.A. Soluble RANKL Contributes to Osteoclast Formation in Adult Mice but Not Ovariectomy-Induced Bone Loss. Nat. Commun. 2018, 9, 2909. [Google Scholar] [CrossRef]
- Wong, B.R.; Rho, J.; Arron, J.; Robinson, E.; Orlinick, J.; Chao, M.; Kalachikov, S.; Cayani, E.; Bartlett, F.S.; Frankel, W.N.; et al. TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates C-Jun N-Terminal Kinase in T Cells. J. Biol. Chem. 1997, 272, 25190–25194. [Google Scholar] [CrossRef] [PubMed]
- Anderson, D.M.; Maraskovsky, E.; Billingsley, W.L.; Dougall, W.C.; Tometsko, M.E.; Roux, E.R.; Teepe, M.C.; DuBose, R.F.; Cosman, D.; Galibert, L. A Homologue of the TNF Receptor and Its Ligand Enhance T-Cell Growth and Dendritic-Cell Function. Nature 1997, 390, 175–179. [Google Scholar] [CrossRef]
- Dougall, W.C.; Glaccum, M.; Charrier, K.; Rohrbach, K.; Brasel, K.; De Smedt, T.; Daro, E.; Smith, J.; Tometsko, M.E.; Maliszewski, C.R.; et al. RANK Is Essential for Osteoclast and Lymph Node Development. Genes. Dev. 1999, 13, 2412–2424. [Google Scholar] [CrossRef] [PubMed]
- Jimi, E.; Akiyama, S.; Tsurukai, T.; Okahashi, N.; Kobayashi, K.; Udagawa, N.; Nishihara, T.; Takahashi, N.; Suda, T. Osteoclast Differentiation Factor Acts as a Multifunctional Regulator in Murine Osteoclast Differentiation and Function. J. Immunol. 1999, 163, 434–442. [Google Scholar] [CrossRef] [PubMed]
- Lacey, D.L.; Timms, E.; Tan, H.-L.; Kelley, M.J.; Dunstan, C.R.; Burgess, T.; Elliott, R.; Colombero, A.; Elliott, G.; Scully, S.; et al. Osteoprotegerin Ligand Is a Cytokine That Regulates Osteoclast Differentiation and Activation. Cell 1998, 93, 165–176. [Google Scholar] [CrossRef] [PubMed]
- Nakashima, T.; Kobayashi, Y.; Yamasaki, S.; Kawakami, A.; Eguchi, K.; Sasaki, H.; Sakai, H. Protein Expression and Functional Difference of Membrane-Bound and Soluble Receptor Activator of NF-κB Ligand: Modulation of the Expression by Osteotropic Factors and Cytokines. Biochem. Biophys. Res. Commun. 2000, 275, 768–775. [Google Scholar] [CrossRef]
- Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; et al. Osteoclast Differentiation Factor Is a Ligand for Osteoprotegerin/Osteoclastogenesis-Inhibitory Factor and Is Identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 1998, 95, 3597–3602. [Google Scholar] [CrossRef]
- Asano, T.; Okamoto, K.; Nakai, Y.; Tsutsumi, M.; Muro, R.; Suematsu, A.; Hashimoto, K.; Okamura, T.; Ehata, S.; Nitta, T.; et al. Soluble RANKL Is Physiologically Dispensable but Accelerates Tumour Metastasis to Bone. Nat. Metab. 2019, 1, 868–875. [Google Scholar] [CrossRef]
- Tsukasaki, M.; Asano, T.; Muro, R.; Huynh, N.C.-N.; Komatsu, N.; Okamoto, K.; Nakano, K.; Okamura, T.; Nitta, T.; Takayanagi, H. OPG Production Matters Where It Happened. Cell Rep. 2020, 32, 108124. [Google Scholar] [CrossRef] [PubMed]
- Simonet, W.S.; Lacey, D.L.; Dunstan, C.R.; Kelley, M.; Chang, M.-S.; Lüthy, R.; Nguyen, H.Q.; Wooden, S.; Bennett, L.; Boone, T.; et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell 1997, 89, 309–319. [Google Scholar] [CrossRef]
- Boyle, W.J.; Simonet, W.S.; Lacey, D.L. Osteoclast Differentiation and Activation. Nature 2003, 423, 337–342. [Google Scholar] [CrossRef] [PubMed]
- Girasole, G.; Passeri, G.; Jilka, R.L.; Manolagas, S.C. Interleukin-11: A New Cytokine Critical for Osteoclast Development. J. Clin. Investig. 1994, 93, 1516–1524. [Google Scholar] [CrossRef]
- Tamura, T.; Udagawa, N.; Takahashi, N.; Miyaura, C.; Tanaka, S.; Yamada, Y.; Koishihara, Y.; Ohsugi, Y.; Kumaki, K.; Taga, T. Soluble Interleukin-6 Receptor Triggers Osteoclast Formation by Interleukin 6. Proc. Natl. Acad. Sci. USA 1993, 90, 11924–11928. [Google Scholar] [CrossRef]
- Suda, T.; Takahashi, N.; Udagawa, N.; Jimi, E.; Gillespie, M.T.; Martin, T.J. Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families. Endocr. Rev. 1999, 20, 345–357. [Google Scholar] [CrossRef] [PubMed]
- Akdeniz, N.; Akpolat, V.; Kale, A.; Erdemoglu, M.; Kuyumcuoglu, U.; Celik, Y. Risk Factors for Postmenopausal Osteoporosis: Anthropometric Measurements, Age, Age at Menopause and the Time Elapsed after Menopause Onset. Gynecol Endocrinol 2009, 25, 125–129. [Google Scholar] [CrossRef]
- Wang, L.-T.; Chen, L.-R.; Chen, K.-H. Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview. Int J Mol Sci 2023, 24, 5814. [Google Scholar] [CrossRef] [PubMed]
- Regulation of Bone Formation by Osteoclasts Involves Wnt/BMP Signaling and the Chemokine Sphingosine-1-Phosphate|PNAS. Available online: https://www.pnas.org/doi/full/10.1073/pnas.0805133106 (accessed on 13 August 2024).
- Vasiliadis, E.S.; Evangelopoulos, D.-S.; Kaspiris, A.; Benetos, I.S.; Vlachos, C.; Pneumaticos, S.G. The Role of Sclerostin in Bone Diseases. J. Clin. Med. 2022, 11, 806. [Google Scholar] [CrossRef]
- Kong, Y.-Y.; Yoshida, H.; Sarosi, I.; Tan, H.-L.; Timms, E.; Capparelli, C.; Morony, S.; Oliveira-dos-Santos, A.J.; Van, G.; Itie, A.; et al. OPGL Is a Key Regulator of Osteoclastogenesis, Lymphocyte Development and Lymph-Node Organogenesis. Nature 1999, 397, 315–323. [Google Scholar] [CrossRef]
- Bucay, N.; Sarosi, I.; Dunstan, C.R.; Morony, S.; Tarpley, J.; Capparelli, C.; Scully, S.; Tan, H.L.; Xu, W.; Lacey, D.L.; et al. Osteoprotegerin-Deficient Mice Develop Early Onset Osteoporosis and Arterial Calcification. Genes. Dev. 1998, 12, 1260–1268. [Google Scholar] [CrossRef]
- Mizuno, A.; Amizuka, N.; Irie, K.; Murakami, A.; Fujise, N.; Kanno, T.; Sato, Y.; Nakagawa, N.; Yasuda, H.; Mochizuki, S.; et al. Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/Osteoprotegerin. Biochem. Biophys. Res. Commun. 1998, 247, 610–615. [Google Scholar] [CrossRef]
- Nagashima, K.; Sawa, S.; Nitta, T.; Tsutsumi, M.; Okamura, T.; Penninger, J.M.; Nakashima, T.; Takayanagi, H. Identification of Subepithelial Mesenchymal Cells That Induce IgA and Diversify Gut Microbiota. Nat. Immunol. 2017, 18, 675–682. [Google Scholar] [CrossRef] [PubMed]
- Tsukasaki, M.; Takayanagi, H. Osteoimmunology: Evolving Concepts in Bone–Immune Interactions in Health and Disease. Nat. Rev. Immunol. 2019, 19, 626–642. [Google Scholar] [CrossRef] [PubMed]
- Kiel, D.P.; Kauppila, L.I.; Cupples, L.A.; Hannan, M.T.; O’Donnell, C.J.; Wilson, P.W.F. Bone Loss and the Progression of Abdominal Aortic Calcification over a 25 Year Period: The Framingham Heart Study. Calcif. Tissue Int. 2001, 68, 271–276. [Google Scholar] [CrossRef]
- Schulz, E.; Arfai, K.; Liu, X.; Sayre, J.; Gilsanz, V. Aortic Calcification and the Risk of Osteoporosis and Fractures. J. Clin. Endocrinol. Metab. 2004, 89, 4246–4253. [Google Scholar] [CrossRef]
- Van Campenhout, A.; Golledge, J. Osteoprotegerin, Vascular Calcification and Atherosclerosis. Atherosclerosis 2009, 204, 321–329. [Google Scholar] [CrossRef]
- An, J.-J.; Han, D.-H.; Kim, D.-M.; Kim, S.-H.; Rhee, Y.; Lee, E.-J.; Lim, S.-K. Expression and Regulation of Osteoprotegerin in Adipose Tissue. Yonsei Med. J. 2007, 48, 765. [Google Scholar] [CrossRef] [PubMed]
- Matsuo, F.S.; de Araújo, P.H.C.; Mota, R.F.; Carvalho, A.J.R.; de Queiroz, M.S.; de Almeida, B.B.; Ferreira, K.C.d.O.S.; Metzner, R.J.M.; Ferrari, G.D.; Alberici, L.C.; et al. RANKL Induces Beige Adipocyte Differentiation in Preadipocytes. Am. J. Physiol.-Endocrinol. Metab. 2020, 318, E866–E877. [Google Scholar] [CrossRef] [PubMed]
- Schrader, J.; Rennekamp, W.; Niebergall, U.; Schoppet, M.; Jahr, H.; Brendel, M.D.; Hörsch, D.; Hofbauer, L.C. Cytokine-Induced Osteoprotegerin Expression Protects Pancreatic Beta Cells through P38 Mitogen-Activated Protein Kinase Signalling against Cell Death. Diabetologia 2007, 50, 1243–1247. [Google Scholar] [CrossRef]
- Vachliotis, I.D.; Polyzos, S.A. Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease. Curr. Obes. Rep. 2023, 12, 147–162. [Google Scholar] [CrossRef]
- Nikseresht, M.; Azarmehr, N.; Arya, A.; Alipoor, B.; Fadaei, R.; Khalvati, B.; Abidi, H.; Doustimotlagh, A.H. Circulating mRNA and Plasma Levels of Osteoprotegerin and Receptor Activator of NF-κB Ligand in Nonalcoholic Fatty Liver Disease. Biotechnol. Appl. Biochem. 2021, 68, 1243–1249. [Google Scholar] [CrossRef]
- Hadinia, A.; Doustimotlagh, A.H.; Goodarzi, H.R.; Arya, A.; Jafarinia, M. Plasma Levels and Gene Expression of RANK in Non-Alcoholic Fatty Liver Disease. Clin. Lab. 2020, 66, 793–799. [Google Scholar] [CrossRef] [PubMed]
- Yilmaz, Y.; Yonal, O.; Kurt, R.; Oral, A.Y.; Eren, F.; Ozdogan, O.; Ari, F.; Celikel, C.A.; Korkmaz, S.; Ulukaya, E.; et al. Serum Levels of Osteoprotegerin in the Spectrum of Nonalcoholic Fatty Liver Disease. Scand. J. Clin. Lab. Investig. 2010, 70, 541–546. [Google Scholar] [CrossRef] [PubMed]
- Niu, Y.; Zhang, W.; Yang, Z.; Li, X.; Fang, W.; Zhang, H.; Wang, S.; Zhou, H.; Fan, J.; Qin, L.; et al. Plasma Osteoprotegerin Levels Are Inversely Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Case–Control Study in China. Metabolism 2016, 65, 475–481. [Google Scholar] [CrossRef]
- Zhang, C.; Luo, X.; Chen, J.; Zhou, B.; Yang, M.; Liu, R.; Liu, D.; Gu, H.F.; Zhu, Z.; Zheng, H.; et al. Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK–PPAR-γ–CD36 Pathway. Diabetes 2019, 68, 1902–1914. [Google Scholar] [CrossRef]
- Monseu, M.; Dubois, S.; Boursier, J.; Aubé, C.; Gagnadoux, F.; Lefthériotis, G.; Ducluzeau, P.-H. Osteoprotegerin Levels Are Associated with Liver Fat and Liver Markers in Dysmetabolic Adults. Diabetes Metab. 2016, 42, 364–367. [Google Scholar] [CrossRef]
- Prystupa, A.; Dąbrowska, A.; Sak, J.J.; Tarach, J.; Toruń-Jurkowska, A.; Lachowska-Kotowska, P.; Dzida, G. Concentrations of Fetuin-A, Osteoprotegerin and α-Klotho in Patients with Alcoholic Liver Cirrhosis. Exp. Ther. Med. 2016, 12, 3464–3470. [Google Scholar] [CrossRef] [PubMed]
- García-Valdecasas-Campelo, E.; González-Reimers, E.; Santolaria-Fernández, f.; De La Vega-Prieto, M.J.; Milena-Abril, A.; Sánchez-Pérez, M.J.; Martínez-Riera, A.; Gómez-Rodríguez, M.D.L.Á. Serum Osteoprotegerin and Rankl Levels in Chronic Alcoholic Liver Disease. Alcohol. Alcohol. 2006, 41, 261–266. [Google Scholar] [CrossRef]
- Guañabens, N.; Enjuanes, A.; Alvarez, L.; Peris, P.; Caballería, L.; Jesús Martínez de Osaba, M.; Cerdá, D.; Monegal, A.; Pons, F.; Parés, A. High Osteoprotegerin Serum Levels in Primary Biliary Cirrhosis Are Associated with Disease Severity but Not with the mRNA Gene Expression in Liver Tissue. J. Bone Miner. Metab. 2009, 27, 347–354. [Google Scholar] [CrossRef]
- Lleo, A.; Bian, Z.; Zhang, H.; Miao, Q.; Yang, F.; Peng, Y.; Chen, X.; Tang, R.; Wang, Q.; Qiu, D.; et al. Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS ONE 2016, 11, e0159612. [Google Scholar] [CrossRef]
- DiStefano, J.K. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology 2020, 161, bqaa134. [Google Scholar] [CrossRef]
- Zaidi, M.; Kim, S.-M.; Mathew, M.; Korkmaz, F.; Sultana, F.; Miyashita, S.; Gumerova, A.A.; Frolinger, T.; Moldavski, O.; Barak, O.; et al. Bone Circuitry and Interorgan Skeletal Crosstalk. Elife 2023, 12, e83142. [Google Scholar] [CrossRef] [PubMed]
- Ishii, M.; Egen, J.G.; Klauschen, F.; Meier-Schellersheim, M.; Saeki, Y.; Vacher, J.; Proia, R.L.; Germain, R.N. Sphingosine-1-Phosphate Mobilizes Osteoclast Precursors and Regulates Bone Homeostasis. Nature 2009, 458, 524–528. [Google Scholar] [CrossRef] [PubMed]
- Sukocheva, O.A.; Neganova, M.E.; Aleksandrova, Y.; Burcher, J.T.; Chugunova, E.; Fan, R.; Tse, E.; Sethi, G.; Bishayee, A.; Liu, J. Signaling Controversy and Future Therapeutical Perspectives of Targeting Sphingolipid Network in Cancer Immune Editing and Resistance to Tumor Necrosis Factor-α Immunotherapy. Cell Commun. Signal 2024, 22, 251. [Google Scholar] [CrossRef] [PubMed]
- Grander, C.; Grabherr, F.; Tilg, H. Non-Alcoholic Fatty Liver Disease: Pathophysiological Concepts and Treatment Options. Cardiovasc. Res. 2023, 119, 1787–1798. [Google Scholar] [CrossRef]
- Kiechl, S.; Wittmann, J.; Giaccari, A.; Knoflach, M.; Willeit, P.; Bozec, A.; Moschen, A.R.; Muscogiuri, G.; Sorice, G.P.; Kireva, T.; et al. Blockade of Receptor Activator of Nuclear Factor-κB (RANKL) Signaling Improves Hepatic Insulin Resistance and Prevents Development of Diabetes Mellitus. Nat. Med. 2013, 19, 358–363. [Google Scholar] [CrossRef]
- Rocha, A.L.L.; Faria, L.C.; Guimarães, T.C.M.; Moreira, G.V.; Cândido, A.L.; Couto, C.A.; Reis, F.M. Non-Alcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. J. Endocrinol. Investig. 2017, 40, 1279–1288. [Google Scholar] [CrossRef] [PubMed]
- Kumarendran, B.; O’Reilly, M.W.; Manolopoulos, K.N.; Toulis, K.A.; Gokhale, K.M.; Sitch, A.J.; Wijeyaratne, C.N.; Coomarasamy, A.; Arlt, W.; Nirantharakumar, K. Polycystic Ovary Syndrome, Androgen Excess, and the Risk of Nonalcoholic Fatty Liver Disease in Women: A Longitudinal Study Based on a United Kingdom Primary Care Database. PLoS Med. 2018, 15, e1002542. [Google Scholar] [CrossRef] [PubMed]
- Lu, N.; Shan, C.; Fu, J.-R.; Zhang, Y.; Wang, Y.-Y.; Zhu, Y.-C.; Yu, J.; Cai, J.; Li, S.-X.; Tao, T.; et al. RANKL Is Independently Associated with Increased Risks of Non-Alcoholic Fatty Liver Disease in Chinese Women with PCOS: A Cross-Sectional Study. JCM 2023, 12, 451. [Google Scholar] [CrossRef] [PubMed]
- Alabdulaali, B.; Al-rashed, F.; Al-Onaizi, M.; Kandari, A.; Razafiarison, J.; Tonui, D.; Williams, M.R.; Blériot, C.; Ahmad, R.; Alzaid, F. Macrophages and the Development and Progression of Non-Alcoholic Fatty Liver Disease. Front. Immunol. 2023, 14, 1195699. [Google Scholar] [CrossRef]
- Sutti, S.; Bruzzì, S.; Albano, E. The Role of Immune Mechanisms in Alcoholic and Nonalcoholic Steatohepatitis: A 2015 Update. Expert Rev. Gastroenterol. Hepatol. 2016, 10, 243–253. [Google Scholar] [CrossRef]
- Zhong, L.; Yuan, J.; Huang, L.; Li, S.; Deng, L. RANKL Is Involved in Runx2-Triggered Hepatic Infiltration of Macrophages in Mice with NAFLD Induced by a High-Fat Diet. BioMed. Res. Int. 2020, 2020, 1–8. [Google Scholar] [CrossRef]
- Lin, T.-C. RUNX2 and Cancer. IJMS 2023, 24, 7001. [Google Scholar] [CrossRef] [PubMed]
- Zhong, L.; Huang, L.; Xue, Q.; Liu, C.; Xu, K.; Shen, W.; Deng, L. Cell-Specific Elevation of Runx2 Promotes Hepatic Infiltration of Macrophages by Upregulating MCP-1 in High-Fat Diet-Induced Mice NAFLD. J. Cell Biochem. 2019, 120, 11761–11774. [Google Scholar] [CrossRef] [PubMed]
- Toffoli, B.; Pickering, R.J.; Tsorotes, D.; Wang, B.; Bernardi, S.; Kantharidis, P.; Fabris, B.; Zauli, G.; Secchiero, P.; Thomas, M.C. Osteoprotegerin Promotes Vascular Fibrosis via a TGF-Β1 Autocrine Loop. Atherosclerosis 2011, 218, 61–68. [Google Scholar] [CrossRef]
- Kamm, D.R.; McCommis, K.S. Hepatic stellate cells in physiology and pathology. J. Physiol. 2022, 600, 1825–1837. [Google Scholar] [CrossRef] [PubMed]
- Adhyatmika, A.; Beljaars, L.; Putri, K.S.S.; Habibie, H.; Boorsma, C.E.; Reker-Smit, C.; Luangmonkong, T.; Guney, B.; Haak, A.; Mangnus, K.A.; et al. Osteoprotegerin Is More than a Possible Serum Marker in Liver Fibrosis: A Study into Its Function in Human and Murine Liver. Pharmaceutics 2020, 12, 471. [Google Scholar] [CrossRef] [PubMed]
- Adhyatmika, A.; Putri, K.S.S.; Gore, E.; Mangnus, K.A.; Reker-Smit, C.; Schuppan, D.; Beljaars, L.; Olinga, P.; Melgert, B.N. Osteoprotegerin Expression in Liver Is Induced by IL13 through TGF&beta. Cell. Physiol. Biochem. 2022, 56, 28–38. [Google Scholar]
- Wynn, T.A.; Barron, L. Macrophages: Master Regulators of Inflammation and Fibrosis. Semin. Liver Dis. 2010, 30, 245–257. [Google Scholar] [CrossRef]
- Reid, P.; Holen, I. Pathophysiological Roles of Osteoprotegerin (OPG). Eur. J. Cell Biol. 2009, 88, 1–17. [Google Scholar] [CrossRef]
- Guerrache, A.; Micheau, O. TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling. Cells 2024, 13, 521. [Google Scholar] [CrossRef] [PubMed]
- Jo, M.; Kim, T.-H.; Seol, D.-W.; Esplen, J.E.; Dorko, K.; Billiar, T.R.; Strom, S.C. Apoptosis Induced in Normal Human Hepatocytes by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Nat. Med. 2000, 6, 564–567. [Google Scholar] [CrossRef] [PubMed]
- Cartland, S.P.; Harith, H.H.; Genner, S.W.; Dang, L.; Cogger, V.C.; Vellozzi, M.; Di Bartolo, B.A.; Thomas, S.R.; Adams, L.A.; Kavurma, M.M. Non-Alcoholic Fatty Liver Disease, Vascular Inflammation and Insulin Resistance Are Exacerbated by TRAIL Deletion in Mice. Sci. Rep. 2017, 7, 1898. [Google Scholar] [CrossRef]
- Zheng, S.-J.; Wang, P.; Tsabary, G.; Chen, Y.H. Critical Roles of TRAIL in Hepatic Cell Death and Hepatic Inflammation. Available online: https://www.jci.org/articles/view/19255/pdf (accessed on 23 June 2024).
- Han, L.-H.; Sun, W.-S.; Ma, C.-H.; Zhang, L.-N.; Liu, S.-X.; Zhang, Q.; Gao, L.-F.; Chen, Y.-H. Detection of Soluble TRAIL in HBV Infected Patients and Its Clinical Implications. World J. Gastroenterol. 2002, 8, 1077–1080. [Google Scholar] [CrossRef] [PubMed]
- Musso, G.; Gambino, R.; Cassader, M. Cholesterol Metabolism and the Pathogenesis of Non-Alcoholic Steatohepatitis. Progress. Lipid Res. 2013, 52, 175–191. [Google Scholar] [CrossRef]
- Von Karstedt, S.; Montinaro, A.; Walczak, H. Exploring the TRAILs Less Travelled: TRAIL in Cancer Biology and Therapy. Nat. Rev. Cancer 2017, 17, 352–366. [Google Scholar] [CrossRef] [PubMed]
- Holen, I.; Croucher, P.I.; Hamdy, F.C.; Eaton, C.L. Osteoprotegerin (OPG) Is a Survival Factor for Human Prostate Cancer Cells. Cancer Res. 2002, 62, 1619–1623. [Google Scholar]
- Nyambo, R.; Cross, N.; Lippitt, J.; Holen, I.; Bryden, G.; Hamdy, F.C.; Eaton, C.L. Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL-Induced Apoptosis. J. Bone Miner. Res. 2004, 19, 1712–1721. [Google Scholar] [CrossRef] [PubMed]
- Neville-Webbe, H.L.; Cross, N.A.; Eaton, C.L.; Nyambo, R.; Evans, C.A.; Coleman, R.E.; Holen, I. Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis. Breast Cancer Res. Treat. 2004, 86, 269–279. [Google Scholar] [CrossRef] [PubMed]
- Holen, I.; Cross, S.S.; Neville-Webbe, H.L.; Cross, N.A.; Balasubramanian, S.P.; Croucher, P.I.; Evans, C.A.; Lippitt, J.M.; Coleman, R.E.; Eaton, C.L. Osteoprotegerin (OPG) Expression by Breast Cancer Cells in Vitro and Breast Tumours in Vivo—A Role in Tumour Cell Survival? Breast Cancer Res. Treat. 2005, 92, 207–215. [Google Scholar] [CrossRef] [PubMed]
- De Toni, E.; Nagel, D.; Philipp, A.B.; Herbst, A.; Thalhammer, I.; Mayerle, J.; Török, H.-P.; Brandl, L.; Kolligs, F.T. Correlation Between Baseline Osteoprotegerin Serum Levels and Prognosis of Advanced-Stage Colorectal Cancer Patients. Cell. Physiol. Biochem. 2018, 45, 605–613. [Google Scholar] [CrossRef]
- Shi, W.; Qiu, W.; Wang, W.; Zhou, X.; Zhong, X.; Tian, G.; Deng, A. Osteoprotegerin Is Up-Regulated in Pancreatic Cancers and Correlates with Cancer-Associated New-Onset Diabetes. BioScience Trends 2014, 8, 322–326. [Google Scholar] [CrossRef] [PubMed]
- Cummings, S.R.; Martin, J.S.; McClung, M.R.; Siris, E.S.; Eastell, R.; Reid, I.R.; Delmas, P.; Zoog, H.B.; Austin, M.; Wang, A.; et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. New Engl. J. Med. 2009, 361, 756–765. [Google Scholar] [CrossRef] [PubMed]
- Baron, R.; Ferrari, S.; Russell, R.G.G. Denosumab and Bisphosphonates: Different Mechanisms of Action and Effects. Bone 2011, 48, 677–692. [Google Scholar] [CrossRef]
- Brown, J.P.; Prince, R.L.; Deal, C.; Recker, R.R.; Kiel, D.P.; de Gregorio, L.H.; Hadji, P.; Hofbauer, L.C.; Alvaro-Gracia, J.M.; Wang, H.; et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. J. Bone Miner. Res. 2009, 24, 153–161. [Google Scholar] [CrossRef] [PubMed]
- Kendler, D.L.; Roux, C.; Benhamou, C.L.; Brown, J.P.; Lillestol, M.; Siddhanti, S.; Man, H.-S.; San Martin, J.; Bone, H.G. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning from Alendronate Therapy. J. Bone Miner. Res. 2010, 25, 72–81. [Google Scholar] [CrossRef] [PubMed]
- Saeki, C.; Saito, M.; Oikawa, T.; Nakano, M.; Torisu, Y.; Saruta, M.; Tsubota, A. Effects of Denosumab Treatment in Chronic Liver Disease Patients with Osteoporosis. WJG 2020, 26, 4960–4971. [Google Scholar] [CrossRef]
- Takeno, A.; Yamamoto, M.; Notsu, M.; Sugimoto, T. Administration of Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) Antibody for the Treatment of Osteoporosis Was Associated with Amelioration of Hepatitis in a Female Patient with Growth Hormone Deficiency: A Case Report. BMC Endocr. Disord. 2016, 16, 66. [Google Scholar] [CrossRef] [PubMed]
- Weivoda, M.M.; Chew, C.K.; Monroe, D.G.; Farr, J.N.; Atkinson, E.J.; Geske, J.R.; Eckhardt, B.; Thicke, B.; Ruan, M.; Tweed, A.J.; et al. Identification of Osteoclast-Osteoblast Coupling Factors in Humans Reveals Links between Bone and Energy Metabolism. Nat. Commun. 2020, 11, 87. [Google Scholar] [CrossRef] [PubMed]
- Huang, H.-K.; Chuang, A.T.-M.; Liao, T.-C.; Shao, S.-C.; Liu, P.P.-S.; Tu, Y.-K.; Lai, E.C.-C. Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis. JAMA Netw. Open 2024, 7, e2354734. [Google Scholar] [CrossRef]
- Hasuzawa, N.; Tatsushima, K.; Wang, L.; Kabashima, M.; Tokubuchi, R.; Nagayama, A.; Ashida, K.; Ogawa, Y.; Moriyama, Y.; Nomura, M. Clodronate, an Inhibitor of the Vesicular Nucleotide Transporter, Ameliorates Steatohepatitis and Acute Liver Injury. Sci. Rep. 2021, 11, 5192. [Google Scholar] [CrossRef]
- Vaughn, B.P.; Robson, S.C.; Burnstock, G. Pathological Roles of Purinergic Signaling in the Liver. J. Hepatol. 2012, 57, 916–920. [Google Scholar] [CrossRef]
- Tatsushima, K.; Hasuzawa, N.; Wang, L.; Hiasa, M.; Sakamoto, S.; Ashida, K.; Sudo, N.; Moriyama, Y.; Nomura, M. Vesicular ATP Release from Hepatocytes Plays a Role in the Progression of Nonalcoholic Steatohepatitis. Biochim. Biophys. Acta Mol. Basis Dis. 2021, 1867, 166013. [Google Scholar] [CrossRef]
- Tang, Q.; Jiang, S.; Jia, W.; Shen, D.; Qiu, Y.; Zhao, Y.; Xue, B.; Li, C. Zoledronic Acid, an FPPS Inhibitor, Ameliorates Liver Steatosis through Inhibiting Hepatic de Novo Lipogenesis. Eur. J. Pharmacol. 2017, 814, 169–177. [Google Scholar] [CrossRef] [PubMed]
- Mohamed, R.H.; Tarek, M.; Hamam, G.G.; Ezzat, S.F. Zoledronic Acid Prevents the Hepatic Changes Associated with High Fat Diet in Rats; the Potential Role of Mevalonic Acid Pathway in Nonalcoholic Steatohepatitis. Eur. J. Pharmacol. 2019, 858, 172469. [Google Scholar] [CrossRef] [PubMed]
- Canalis, E. Management of Endocrine Disease: Novel Anabolic Treatments for Osteoporosis. Eur. J. Endocrinol. 2018, 178, R33–R44. [Google Scholar] [CrossRef]
- Forner, A.; Reig, M.; Bruix, J. Hepatocellular Carcinoma. Lancet 2018, 391, 1301–1314. [Google Scholar] [CrossRef]
- Younossi, Z.M.; Otgonsuren, M.; Henry, L.; Venkatesan, C.; Mishra, A.; Erario, M.; Hunt, S. Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015, 62, 1723–1730. [Google Scholar] [CrossRef] [PubMed]
- Estes, C.; Anstee, Q.M.; Arias-Loste, M.T.; Bantel, H.; Bellentani, S.; Caballeria, J.; Colombo, M.; Craxi, A.; Crespo, J.; Day, C.P.; et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016–2030. J. Hepatol. 2018, 69, 896–904. [Google Scholar] [CrossRef] [PubMed]
- Piscaglia, F.; Svegliati-Baroni, G.; Barchetti, A.; Pecorelli, A.; Marinelli, S.; Tiribelli, C.; Bellentani, S.; HCC-NAFLD Italian Study Group. Clinical Patterns of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Multicenter Prospective Study. Hepatology 2016, 63, 827. [Google Scholar] [CrossRef]
- Song, F.-N.; Duan, M.; Liu, L.-Z.; Wang, Z.-C.; Shi, J.-Y.; Yang, L.-X.; Zhou, J.; Fan, J.; Gao, Q.; Wang, X.-Y. RANKL Promotes Migration and Invasion of Hepatocellular Carcinoma Cells via NF-κB-Mediated Epithelial-Mesenchymal Transition. PLoS ONE 2014, 9, e108507. [Google Scholar] [CrossRef]
- Tsubaki, M.; Komai, M.; Fujimoto, S.; Itoh, T.; Imano, M.; Sakamoto, K.; Shimaoka, H.; Takeda, T.; Ogawa, N.; Mashimo, K.; et al. Activation of NF-κB by the RANKL/RANK System up-Regulates Snail and Twist Expressions and Induces Epithelial-to-Mesenchymal Transition in Mammary Tumor Cell Lines. J. Exp. Clin. Cancer Res. 2013, 32, 62. [Google Scholar] [CrossRef]
- Jiang, R.; Xia, Y.; Li, J.; Deng, L.; Zhao, L.; Shi, J.; Wang, X.; Sun, B. High Expression Levels of IKKα and IKKβ Are Necessary for the Malignant Properties of Liver Cancer. Int. J. Cancer 2010, 126, 1263–1274. [Google Scholar] [CrossRef] [PubMed]
- Sasaki, A.; Ishikawa, K.; Haraguchi, N.; Inoue, H.; Ishio, T.; Shibata, K.; Ohta, M.; Kitano, S.; Mori, M. Receptor Activator of Nuclear Factor-κB Ligand (RANKL) Expression in Hepatocellular Carcinoma With Bone Metastasis. Ann. Surg. Oncol. 2007, 14, 1191–1199. [Google Scholar] [CrossRef]
- Qing, T.; Yamin, Z.; Guijie, W.; Yan, J.; Zhongyang, S. STAT6 Silencing Induces Hepatocellular Carcinoma-Derived Cell Apoptosis and Growth Inhibition by Decreasing the RANKL Expression. Biomed. Pharmacother. 2017, 92, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.-J.; Zhang, C.; Martincuks, A.; Herrmann, A.; Yu, H. STAT Proteins in Cancer: Orchestration of Metabolism. Nat. Rev. Cancer 2023, 23, 115–134. [Google Scholar] [CrossRef] [PubMed]
- Erdogan, F.; Radu, T.B.; Orlova, A.; Qadree, A.K.; de Araujo, E.D.; Israelian, J.; Valent, P.; Mustjoki, S.M.; Herling, M.; Moriggl, R.; et al. JAK-STAT Core Cancer Pathway: An Integrative Cancer Interactome Analysis. J. Cell Mol. Med. 2022, 26, 2049–2062. [Google Scholar] [CrossRef] [PubMed]
- Liao, Y.; Cai, B.; Li, Y.; Wang, L. P0360: STAT6 Rs3024974 Might Predict Worse Prognosis in Hepatocellular Carcinoma Patients. J. Hepatol. 2015, 62, S445–S446. [Google Scholar] [CrossRef]
- Zhang, C.; Lin, J.; Ni, X.; Li, H.; Zheng, L.; Zhao, Z.; Qi, X.; Huo, H.; Lou, X.; Fan, Q.; et al. Prognostic Value of Serum Osteoprotegerin Level in Patients With Hepatocellular Carcinoma Following Surgical Resection. Front. Oncol. 2021, 11, 731989. [Google Scholar] [CrossRef]
- Gao, Y.-B.; Xiang, Z.-L.; Zhou, L.-Y.; Wu, Z.-F.; Fan, J.; Zeng, H.-Y.; Zeng, Z.-C. Enhanced Production of CTGF and IL-11 from Highly Metastatic Hepatoma Cells under Hypoxic Conditions: An Implication of Hepatocellular Carcinoma Metastasis to Bone. J. Cancer Res. Clin. Oncol. 2013, 139, 669–679. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Monti, F.; Perazza, F.; Leoni, L.; Stefanini, B.; Ferri, S.; Tovoli, F.; Zavatta, G.; Piscaglia, F.; Petroni, M.L.; Ravaioli, F. RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives. Int. J. Mol. Sci. 2024, 25, 9193. https://doi.org/10.3390/ijms25179193
Monti F, Perazza F, Leoni L, Stefanini B, Ferri S, Tovoli F, Zavatta G, Piscaglia F, Petroni ML, Ravaioli F. RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives. International Journal of Molecular Sciences. 2024; 25(17):9193. https://doi.org/10.3390/ijms25179193
Chicago/Turabian StyleMonti, Federico, Federica Perazza, Laura Leoni, Bernardo Stefanini, Silvia Ferri, Francesco Tovoli, Guido Zavatta, Fabio Piscaglia, Maria Letizia Petroni, and Federico Ravaioli. 2024. "RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives" International Journal of Molecular Sciences 25, no. 17: 9193. https://doi.org/10.3390/ijms25179193